Sneaker Resale Is Trending to Hit $30B Worldwide by 2030 — Here’s Where People Are Shopping on StockX Globally

StockX is a major player in the worldwide sneaker resale market. And the latest report from the “stock market of things” details its recent international successes.

Today, the company released “StockX Snapshot: Resale is a Global Game,” which outlines the growth it experienced outside of the U.S. for Q3 2020, as well as several trends that have emerged. StockX started the report by citing an estimation by Cowen Equity Research, which states the global sneaker resale market will hit $30 billion by 2030, including $19 billion outside of the states.

The report reveals several areas of growth outside of the U.S. for StockX including sell-side transactions (up 260% year-over-year), the number of female users (up 130%) and the number of users 25 years old or younger (up 62% for Q3). Also, the company stated it hit 25 million monthly global visitors in Q3.

For several key markets, StockX detailed the best sellers. In France, for instance, the Air Jordan 1 Mid “Maison Chateau Rouge” was the No. 2 best-seller and was purchased 21 times the global average. In the UK, the Air Jordan 1 Mid “Pink Quartz” in grade school sizing was the No. 2 best-seller and was purchased nine times the global average. Germany’s No. 7 best-seller was the Adidas ZX 8000 OG “Aqua” that sold 43 times the global average and Japan’s No. 4 best-seller was the Levi’s x New Balance 1300 that sold 51 times the global average.

StockX also revealed the biggest sneaker imports and exports in key markets, comparing them to that of other categories. In France, for instance, the Adidas Yeezy Boost 350 V2 “Zyon” accounted for 1.9% of Q3 sneaker imports compared to cars, which accounted for 6.1%. As for exports, the Dior x Air Jordan 1 Low and High accounted for 5.1% of Q3 sneaker exports, compared to aircrafts that account for 7.8%.

Similarly in Japan, the Nike Air Max 95 “Denham” was 7.1% of Q3 sneaker imports, which StockX compared to packaged medicine, which was 2.1%.

Access exclusive content